I'm Calling It: Hims & Hers Health Will Soar 56% by the End of 2026

Hims & Hers is projected to generate $3.99 billion in 2027 revenue versus $3.21 billion expected in 2026; applying a 2.5x sales multiple would imply a roughly $42.76 share price, or 55.7% upside from $27.47. Q2 revenue rose 38% year over year to $753 million, supported by 19% subscriber growth to 2.9 million and a 21% increase in monthly revenue per subscriber to $92. However, gross margin fell 12 percentage points to 64% and adjusted EBITDA declined 26.7% to $60.3 million, leaving profitability in lower-margin weight-loss and international operations as the central risk.

Analysis

The relevant debate is not whether HIMS can sustain top-line growth, but whether its customer-acquisition and fulfillment economics permit incremental EBITDA conversion. A 12-point gross-margin decline alongside weaker domestic growth suggests the current product mix is shifting toward lower-quality revenue; absent stabilization, a sales-multiple rerating is unlikely and the equity could instead de-rate toward lower-margin digital-health peers. International acquisition revenue also carries integration and organic-growth-quality risk that will become more visible over the next two earnings prints.

Near term, subscriber monetization remains a powerful offset: higher revenue per subscriber can support revenue upside if retention holds and cross-selling lowers acquisition payback periods. The key 1-3 month catalyst is evidence that weight-loss fulfillment costs, promotional intensity, and international mix have stopped worsening gross margin. For the next 6-18 months, regulatory or supply changes affecting compounded GLP-1 offerings are the principal tail risk; a tighter FDA enforcement posture or reduced branded-drug shortages could impair both product availability and unit economics simultaneously.

Consensus-style upside math assumes the market will reward revenue scale before profitability is proven. The contrarian view is that the stock already embeds a favorable resolution: at roughly 2x forward sales, HIMS is not expensive on revenue, but it is expensive if EBITDA margins are structurally compressed and growth increasingly depends on paid acquisition or acquired international customers. A modest margin recovery would be more valuation-relevant than another revenue beat; conversely, another material gross-margin step-down should dominate subscriber-growth optics.

Key Decisions for Investors

• Maintain a neutral-to-underweight HIMS stance into the next earnings report; do not underwrite a long solely on revenue estimates. Upgrade only if gross margin stabilizes sequentially and EBITDA margin begins recovering while domestic growth reaccelerates; another meaningful year-on-year gross-margin decline falsifies the rerating thesis.
• For event-driven exposure, consider a defined-risk bearish HIMS put spread dated 3-6 months out, sized for earnings volatility. The payoff is attractive if margin pressure forces forward EBITDA estimate cuts; risk is a rapid margin stabilization plus continued subscriber monetization, which could drive a high-short-interest-style multiple expansion.
• Monitor FDA communications on compounded GLP-1s, branded GLP-1 supply-status changes, and HIMS disclosure of weight-loss revenue mix as immediate thesis triggers. Any restriction that reduces compounded-product availability is likely a negative earnings revision catalyst before it becomes visible in reported revenue.
• If post-earnings results show sequential gross-margin improvement with unchanged growth, switch to a tactical long HIMS for a 1-3 month rerating window, targeting a move toward a 2.5x forward-sales valuation. Exit if margin improvement is attributable only to temporary pricing or if customer-acquisition costs rise materially.